Candel Therapeutics (CADL) vs IRulya Therapeutics (IRLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
IRulya Therapeutics is the larger company by market cap ($432.4 million vs $395.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | IRLA |
|---|---|---|
| Share price | $5.04 | $39.88 |
| Market cap | $395.37M | $432.36M |
| 1-day change | -1.75% | -0.15% |
| YTD return | -10.80% | — |
| 1-year return | +10.77% | — |
| 5-year return | -48.47% | — |
| EPS (TTM) | $-1.53 | $-162.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-38.18M | $-83.98M |
| 52-week high | $14.00 | $910.00 |
| 52-week low | $4.35 | $15.10 |
| Distance from 52-week high | -64.00% | -95.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +250.60% | +90.90% |
| Average volume | 1.26M | 63.03K |
| Shares outstanding | 78.45M | 10.84M |
| Employees | 55 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About IRulya Therapeutics
IRLA stock →IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees
CADL vs IRLA FAQ
Which is bigger, Candel Therapeutics or IRulya Therapeutics?
IRulya Therapeutics (IRLA) is larger, with a market capitalization of $432.36M compared with $395.37M for Candel Therapeutics (CADL).
Are Candel Therapeutics and IRulya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.